Abstract | CONTEXT: EVIDENCE ACQUISITION: On June 26, 2021, a systematic search was performed in Medline, Google Scholar, Google book, and Cochrane Library using the terms: " tumor induced osteomalacia," " oncogenic osteomalacia," " hypophosphatemia." There were no language restrictions. This review was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analyses criteria. EVIDENCE RESULTS: Overall, 1725 TIO cases were collected. TIO was more frequent in adult men, who showed a higher incidence of fractures compared with TIO women. The TIO-causing neoplasms were identified in 1493 patients. The somatostatin receptor-based imaging modalities have the highest sensitivity for the identification of TIO-causing neoplasms. TIO-causing neoplasms were equally located in bone and soft tissues; the latter showed a higher prevalence of fractures and deformities. The surgery is the preferred TIO definitive treatment (successful in > 90% of patients). Promising nonsurgical therapies are treatments with burosumab in TIO patients with elevated fibroblast growth factor-23 levels, and with radiolabeled somatostatin analogs in patients with TIO-causing neoplasm identified by somatostatin receptor-based imaging techniques. CONCLUSION: TIO occurs preferentially in adult men. The TIO clinical expressiveness is more severe in men as well as in patients with TIO-causing neoplasms located in soft tissues. Treatments with burosumab and with radiolabeled somatostatin analogs are the most promising nonsurgical therapies.
|
Authors | Domenico Rendina, Veronica Abate, Giuseppe Cacace, Lanfranco D'Elia, Gianpaolo De Filippo, Silvana Del Vecchio, Ferruccio Galletti, Alberto Cuocolo, Pasquale Strazzullo |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 107
Issue 8
Pg. e3428-e3436
(07 14 2022)
ISSN: 1945-7197 [Electronic] United States |
PMID | 35468192
(Publication Type: Journal Article, Systematic Review)
|
Copyright | © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Receptors, Somatostatin
- Somatostatin
- Fibroblast Growth Factors
|
Topics |
- Adult
- Data Analysis
- Female
- Fibroblast Growth Factors
- Humans
- Hypophosphatemia
(epidemiology, etiology)
- Male
- Neoplasms, Connective Tissue
(etiology)
- Osteomalacia
(etiology)
- Paraneoplastic Syndromes
(etiology)
- Receptors, Somatostatin
- Somatostatin
|